uniQure (QURE) AI Stock Analysis

• Market Cap: $3.76B
• Dividend Yield: N/A
• Average Volume (3M): 5.74M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: -48.25%
• EPS Growth: 33.77%
• Country: US
• Employees: 209
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.69
• Shares Outstanding: 61,603,770
• 10 Day Avg. Volume: 1,832,834
• 30 Day Avg. Volume: 5,739,269
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.24
• Enterprise Value/Revenue: 63.40
• Enterprise Value/Gross Profit: 76.75
• Enterprise Value/Ebitda: -6.25
• 1Y Price Target: $75.50
• Price Target Upside: 23.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12

• Rating: 56 Neutral
• Price Target: $65.00 ▲(6.54% Upside)

uniQure's overall stock score is primarily impacted by its precarious financial performance, which poses significant risks. The technical analysis shows positive momentum, providing some optimism. However, the valuation remains unattractive due to ongoing losses. The earnings call offers a mixed outlook with promising clinical advancements but declining revenues. Overall, the stock presents a high-risk profile with potential for future growth contingent on successful clinical developments.

Positive Factors

Regulatory Progress

The breakthrough therapy designation for AMT-130 is a significant regulatory milestone, potentially accelerating its path to market and enhancing uniQure's competitive position in gene therapy for Huntington's disease.

Strong Financial Position

A robust cash position provides uniQure with the financial flexibility to fund ongoing R&D and commercialization efforts, supporting long-term strategic initiatives and reducing reliance on external financing.

Clinical Advances

Significant clinical progress with AMT-260 showcases uniQure's innovative capabilities in gene therapy, potentially leading to new treatment options and expanding its market presence in neurodegenerative diseases.

Negative Factors

Revenue Decline

The sharp decline in revenue highlights challenges in sustaining sales growth, which could impact uniQure's ability to fund future operations and investments without additional capital.

High R&D Expenses

Rising R&D costs reflect increased investment in development programs, which, while necessary for innovation, can pressure margins and profitability if not matched by revenue growth.

Financial Instability

The negative equity position and high leverage indicate financial instability, posing risks to uniQure's long-term solvency and ability to withstand economic downturns or operational setbacks.

uniQure Business Overview & Revenue Model

Company Description

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

How the Company Makes Money

uniQure generates revenue primarily through the commercialization of its gene therapy products, which include marketed products like Zynteglo for beta-thalassemia and other pipeline therapies in late-stage clinical development. The company also earns revenue from research collaborations and licensing agreements with pharmaceutical and biotechnology companies. These partnerships may include upfront payments, milestone payments based on the achievement of specific developmental or regulatory goals, and royalties on future sales of licensed products. Additionally, uniQure may benefit financially from government grants and funding aimed at supporting innovative research in gene therapy.

uniQure Financial Statement Overview

Summary

uniQure is facing significant financial challenges with declining revenues, negative profit margins, and a weak balance sheet. The company's high debt levels and negative equity position raise concerns about its financial stability. While there is a slight improvement in free cash flow, the overall financial health of the company is precarious, requiring strategic interventions to improve profitability and strengthen the balance sheet.

Income Statement

uniQure's income statement reflects significant challenges with declining revenues and negative profit margins. The TTM data shows a sharp revenue decline of 29% and a net profit margin of -13.88%, indicating substantial losses. Despite a high gross profit margin of 82.61% in the TTM, the company struggles with negative EBIT and EBITDA margins, highlighting operational inefficiencies.

Balance Sheet

The balance sheet reveals a concerning financial position with negative stockholders' equity and a high debt-to-equity ratio of -16.66 in the TTM. This indicates financial instability and potential solvency issues. The return on equity is also negative, reflecting ongoing losses and poor returns for shareholders.

Cash Flow

uniQure's cash flow statement shows a slight improvement in free cash flow growth at 4.33% in the TTM, but the operating cash flow remains negative, indicating cash burn. The free cash flow to net income ratio is slightly above 1, suggesting that the company is generating enough cash to cover its net losses, but the overall cash flow situation remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.34M	27.12M	15.84M	106.48M	524.00M	37.51M
Gross Profit	11.84M	8.79M	2.21M	103.14M	499.03M	-84.89M
EBITDA	-145.35M	-160.75M	-253.10M	-108.02M	319.00M	-126.97M
Net Income	-199.00M	-239.56M	-308.48M	-126.79M	329.59M	-125.02M
Balance Sheet
Total Assets	584.89M	556.54M	831.69M	704.96M	809.18M	340.39M
Cash, Cash Equivalents and Short-Term Investments	376.97M	367.52M	617.89M	352.84M	556.26M	244.93M
Total Debt	66.70M	66.06M	138.41M	142.89M	135.72M	71.54M
Total Liabilities	588.89M	563.29M	624.02M	228.96M	213.40M	96.49M
Stockholders Equity	-4.00M	-6.75M	207.67M	476.01M	595.78M	243.91M
Cash Flow
Free Cash Flow	-174.26M	-186.10M	-153.08M	-162.75M	270.52M	-144.31M
Operating Cash Flow	-173.44M	-182.73M	-145.93M	-145.06M	287.96M	-134.83M
Investing Cash Flow	114.22M	162.97M	-205.69M	-182.73M	-67.39M	-9.48M
Financing Cash Flow	21.18M	-59.49M	362.72M	1.45M	94.86M	7.44M

uniQure Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 61.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QURE, the sentiment is Positive. The current price of 61.01 is above the 20-day moving average (MA) of 59.36, above the 50-day MA of 35.41, and above the 200-day MA of 19.18, indicating a bullish trend. The MACD of 7.35 indicates Positive momentum. The RSI at 64.42 is Neutral, neither overbought nor oversold. The STOCH value of 32.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QURE.

uniQure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CVAC	74 Outperform	$1.21B	5.90	―	―	799.36%	―
NTLA	62 Neutral	$2.75B	―	-56.95%	―	14.99%	14.42%
QURE	56 Neutral	$3.76B	―	-427.47%	―	-48.25%	33.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DAWN	50 Neutral	$767.22M	―	-24.75%	―	2190.50%	52.85%
SYRE	43 Neutral	$1.81B	―	-41.00%	―	―	-429.68%
RCKT	40 Underperform	$415.43M	―	-69.65%	―	―	10.36%

uniQure Corporate Events

uniQure Announces Positive Results for Huntington’s Study

On September 24, 2025, uniQure announced positive topline results from its pivotal Phase I/II study of AMT-130 for Huntington’s disease, demonstrating a statistically significant 75% slowing of disease progression at 36 months in high-dose patients, compared to a control group. The study met its primary endpoint and showed favorable trends in secondary endpoints, with AMT-130 being well-tolerated and no new serious adverse events reported since December 2022. The company plans to discuss these results with the FDA, aiming for a Biologic License Application submission in early 2026, potentially impacting the treatment landscape for Huntington’s disease.

The most recent analyst rating on (QURE) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.

uniQure Secures $175 Million Loan Amendment

On September 22, 2025, uniQure N.V. entered into an amendment with Hercules Capital to their existing loan agreement, allowing for an additional $175 million in term loans. This amendment is intended to refinance existing loans and support general corporate purposes, potentially impacting uniQure’s financial flexibility and operational capacity in the biotechnology sector.

The most recent analyst rating on (QURE) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.

uniQure N.V. Earnings Call: Progress Amid Challenges

uniQure N.V. Earnings Call Highlights Progress and Challenges

uniQure Reports Q2 2025 Progress and Financials

uniQure N.V., a leading gene therapy company, is focused on developing transformative treatments for patients with severe medical needs, particularly in the field of genomic medicine. In its latest earnings report for the second quarter of 2025, uniQure highlighted significant progress in its clinical programs and financial stability, setting the stage for future growth.

uniQure Announces $200 Million Sales Agreement

On July 29, 2025, uniQure N.V. announced a sales agreement with Leerink Partners LLC for an at-the-market offering program, allowing the company to sell its ordinary shares worth up to $200 million. This strategic move provides uniQure with flexibility in raising capital, potentially enhancing its financial position and supporting its ongoing operations in the competitive gene therapy market.

The most recent analyst rating on (QURE) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.